vs

Side-by-side financial comparison of Amer Sports, Inc. (AS) and West Pharmaceutical Services (WST). Click either name above to swap in a different company.

Amer Sports, Inc. is the larger business by last-quarter revenue ($1.1B vs $805.0M, roughly 1.3× West Pharmaceutical Services). West Pharmaceutical Services runs the higher net margin — 16.4% vs 1.8%, a 14.6% gap on every dollar of revenue. West Pharmaceutical Services produced more free cash flow last quarter ($175.0M vs $92.2M).

Amer Sports, Inc. is a Finnish multinational sporting equipment division based in Helsinki, Finland. Established in 1950 as an industrial conglomerate with interests as diverse as tobacco trading, ship owning and publishing, Amer has gradually evolved into a multinational firm devoted to the production and marketing of sporting goods. The company employs over 9,700 people. Since 2018, Amer has been a subsidiary of Chinese retail conglomerate Anta Sports.

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin.

AS vs WST — Head-to-Head

Bigger by revenue
AS
AS
1.3× larger
AS
$1.1B
$805.0M
WST
Higher net margin
WST
WST
14.6% more per $
WST
16.4%
1.8%
AS
More free cash flow
WST
WST
$82.8M more FCF
WST
$175.0M
$92.2M
AS

Income Statement — Q1 FY2024 vs Q4 FY2025

Metric
AS
AS
WST
WST
Revenue
$1.1B
$805.0M
Net Profit
$19.0M
$132.1M
Gross Margin
52.8%
37.8%
Operating Margin
12.4%
19.5%
Net Margin
1.8%
16.4%
Revenue YoY
7.5%
Net Profit YoY
1.5%
EPS (diluted)
$0.05
$1.82

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AS
AS
WST
WST
Q4 25
$805.0M
Q3 25
$804.6M
Q2 25
$766.5M
Q1 25
$698.0M
Q4 24
$748.8M
Q3 24
$746.9M
Q2 24
$702.1M
Q1 24
$1.1B
$695.4M
Net Profit
AS
AS
WST
WST
Q4 25
$132.1M
Q3 25
$140.0M
Q2 25
$131.8M
Q1 25
$89.8M
Q4 24
$130.1M
Q3 24
$136.0M
Q2 24
$111.3M
Q1 24
$19.0M
$115.3M
Gross Margin
AS
AS
WST
WST
Q4 25
37.8%
Q3 25
36.6%
Q2 25
35.7%
Q1 25
33.2%
Q4 24
36.5%
Q3 24
35.4%
Q2 24
32.8%
Q1 24
52.8%
33.1%
Operating Margin
AS
AS
WST
WST
Q4 25
19.5%
Q3 25
20.8%
Q2 25
20.1%
Q1 25
15.3%
Q4 24
21.3%
Q3 24
21.6%
Q2 24
18.0%
Q1 24
12.4%
17.7%
Net Margin
AS
AS
WST
WST
Q4 25
16.4%
Q3 25
17.4%
Q2 25
17.2%
Q1 25
12.9%
Q4 24
17.4%
Q3 24
18.2%
Q2 24
15.9%
Q1 24
1.8%
16.6%
EPS (diluted)
AS
AS
WST
WST
Q4 25
$1.82
Q3 25
$1.92
Q2 25
$1.82
Q1 25
$1.23
Q4 24
$1.78
Q3 24
$1.85
Q2 24
$1.51
Q1 24
$0.05
$1.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AS
AS
WST
WST
Cash + ST InvestmentsLiquidity on hand
$791.3M
Total DebtLower is stronger
$202.8M
Stockholders' EquityBook value
$3.2B
Total Assets
$4.3B
Debt / EquityLower = less leverage
0.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AS
AS
WST
WST
Q4 25
$791.3M
Q3 25
$628.5M
Q2 25
$509.7M
Q1 25
$404.2M
Q4 24
$484.6M
Q3 24
$490.9M
Q2 24
$446.2M
Q1 24
$601.8M
Total Debt
AS
AS
WST
WST
Q4 25
$202.8M
Q3 25
$202.7M
Q2 25
$202.6M
Q1 25
$202.6M
Q4 24
$202.6M
Q3 24
$202.6M
Q2 24
$205.8M
Q1 24
$206.2M
Stockholders' Equity
AS
AS
WST
WST
Q4 25
$3.2B
Q3 25
$3.1B
Q2 25
$2.9B
Q1 25
$2.7B
Q4 24
$2.7B
Q3 24
$2.8B
Q2 24
$2.6B
Q1 24
$2.7B
Total Assets
AS
AS
WST
WST
Q4 25
$4.3B
Q3 25
$4.1B
Q2 25
$4.0B
Q1 25
$3.6B
Q4 24
$3.6B
Q3 24
$3.7B
Q2 24
$3.5B
Q1 24
$3.6B
Debt / Equity
AS
AS
WST
WST
Q4 25
0.06×
Q3 25
0.07×
Q2 25
0.07×
Q1 25
0.08×
Q4 24
0.08×
Q3 24
0.07×
Q2 24
0.08×
Q1 24
0.08×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AS
AS
WST
WST
Operating Cash FlowLast quarter
$114.3M
$251.1M
Free Cash FlowOCF − Capex
$92.2M
$175.0M
FCF MarginFCF / Revenue
8.8%
21.7%
Capex IntensityCapex / Revenue
2.1%
9.5%
Cash ConversionOCF / Net Profit
6.02×
1.90×
TTM Free Cash FlowTrailing 4 quarters
$468.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AS
AS
WST
WST
Q4 25
$251.1M
Q3 25
$197.2M
Q2 25
$177.1M
Q1 25
$129.4M
Q4 24
$190.1M
Q3 24
$180.1M
Q2 24
$165.0M
Q1 24
$114.3M
$118.2M
Free Cash Flow
AS
AS
WST
WST
Q4 25
$175.0M
Q3 25
$133.9M
Q2 25
$101.9M
Q1 25
$58.1M
Q4 24
$85.2M
Q3 24
$98.8M
Q2 24
$64.8M
Q1 24
$92.2M
$27.6M
FCF Margin
AS
AS
WST
WST
Q4 25
21.7%
Q3 25
16.6%
Q2 25
13.3%
Q1 25
8.3%
Q4 24
11.4%
Q3 24
13.2%
Q2 24
9.2%
Q1 24
8.8%
4.0%
Capex Intensity
AS
AS
WST
WST
Q4 25
9.5%
Q3 25
7.9%
Q2 25
9.8%
Q1 25
10.2%
Q4 24
14.0%
Q3 24
10.9%
Q2 24
14.3%
Q1 24
2.1%
13.0%
Cash Conversion
AS
AS
WST
WST
Q4 25
1.90×
Q3 25
1.41×
Q2 25
1.34×
Q1 25
1.44×
Q4 24
1.46×
Q3 24
1.32×
Q2 24
1.48×
Q1 24
6.02×
1.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AS
AS

Americas2$409.6M39%
EMEA1$356.9M34%
Greater China3$205.6M20%
Asia Pacific4$78.2M7%

WST
WST

Proprietary Products$661.8M82%
Contract Manufactured Products$143.2M18%
Affiliated Entity$3.3M0%

Related Comparisons